GlaxoSmithKline submits UMEC/VI for approval in EU
Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the EU for UMEC/VI medicine, a product used to treat chronic obstructive pulmonary disease (COPD).
Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the EU for UMEC/VI medicine, a product used to treat chronic obstructive pulmonary disease (COPD).
The companies previously announced the submission of a regulatory application in the US on December 18th.
The firms also plan to make submissions for regulatory approval for UMEC monotherapy later this year.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
![https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748-320-80.jpg)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Glaxo's share price rose 0.44% to 1,379.50p by 13:22.
NR
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Regulator moves to protect access to cash amid branch closures and disappearing ATMs
News The Financial Conduct Authority has told banks to start assessing if local communities have adequate cash access from mid-September
By Marc Shoffman Published
-
VAT hike on private school fees could come earlier than previously expected
The government could start charging VAT on private school fees as soon as January 2025, according to the latest reports. What does it mean for parents?
By Katie Williams Published